Conference on abuse liability assessment of CNS drugs
C.R. Schuster, J. Henningfield ................................................................. S1

Keeping the lid on: a century of drug regulation and control
J. Spillane, W.B. McAllister ............................................................... S5

Guidelines and methodological reviews concerning drug abuse liability assessment
R.L. Balster, G.E. Bigelow .............................................................. S13

Principles of initial experimental drug abuse liability assessment in humans
R.R. Griffiths, G.E. Bigelow, N.A. Ator ........................................ S41

Principles of drug abuse liability assessment in laboratory animals
N.A. Ator, R.R. Griffiths ............................................................... S55

Incorporating the assessment of abuse liability into the drug discovery and development process

Assessing abuse liability in clinical trials
K.T. Brady, R.B. Lydiard, J.V. Brady ........................................ S87

Postmarketing surveillance for drug abuse
C.L. Arften, T.J. Cicero ................................................................. S97

Abuse liability assessment of CNS drugs: conclusions, recommendations, and research priorities
The Expert Panel ........................................................................ S107